Skip to main content
main-content

Free registration

Medicine Matters was developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Our Editorial Board

Editor's pick

25-05-2018 | Castration-resistant prostate cancer | News

Further data support aBSI as a prognostic marker in mCRPC

Prospective data confirm use of the automated Bone Scan Index as an independent prognostic marker of survival and other clinical outcomes in men with metastatic castration-resistant prostate cancer, researchers report.

23-04-2018 | Survivorship | Editorial | Article

Challenges of an aging and increasingly obese breast cancer survivor population: Are we ready?

In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.

11-04-2018 | Liquid biopsy | Themed collection | Collection

Liquid biopsy in oncology

This themed content collection highlights the role of liquid biopsy in the management of patients with solid tumors and evaluates the role of liquid biopsy in different types of cancer.

Latest from across the site

25-05-2018 | Colorectal cancer | News

Worse prognosis for patients with V600E BRAF-mutated colorectal liver metastases

The presence of the BRAF V600E mutation in colorectal liver metastases is associated with a worse prognosis and increased risk for recurrence, according to findings from an international retrospective cohort study.

Source:

JAMA Surg 2018; Advance online publication

25-05-2018 | Castration-resistant prostate cancer | News

Further data support aBSI as a prognostic marker in mCRPC

Prospective data confirm use of the automated Bone Scan Index as an independent prognostic marker of survival and other clinical outcomes in men with metastatic castration-resistant prostate cancer, researchers report.

Source:

JAMA Oncol 2018; Advance online publication

24-05-2018 | Mesothelioma | News

Tremelimumab plus durvalumab active in unresectable mesothelioma

Preliminary results suggest a role for the combination of the CTLA-4 inhibitor tremelimumab and the PD-L1 blocker durvalumab in the treatment of inoperable pleural or peritoneal mesothelioma.

Source:

Lancet Respir Med 2018; Advance online publication

23-05-2018 | Castration-resistant prostate cancer | News

[177Lu]-PSMA-617 shows promise for heavily pretreated mCRPC

Radionuclide treatment with lutetium-177-prostate-specific membrane antigen-617 shows potential for men with metastatic castration-resistant prostate cancer that has progressed after standard therapy, researchers report.

Source:

Lancet Oncol 2018; Advance online publication

22-05-2018 | Gastric cancer | News

Breath test for esophagogastric cancer diagnosis validated

A noninvasive single breath test has potential for the diagnosis of esophagogastric cancer, say researchers.

Source:

JAMA Oncol 2018; Advance online publication

22-05-2018 | NICE | News | Article

approvalsWatch

Atezolizumab receives NICE recommendation for NSCLC

Read more on this UK decision here

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

image credits